CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Thijs Spoor

Chief Executive Officer, Perspective Therapeutics

Search every verified Thijs Spoor interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Thijs Spoor, CEO of Perspective Therapeutics, discussed the company’s work in radiopharmaceuticals during a podcast interview. He explained that the company develops targeted therapies using the alpha-emitting radioisotope lead-212 (Pb212) and highlighted the importance of biodistribution—ensuring the drug accumulates in tumors rather than healthy organs—as a critical factor for therapeutic safety and efficacy. Spoor noted that Perspective Therapeutics invested in a proprietary generator for Pb212 production, addressing historical supply constraints, and described plans for regional manufacturing, including construction of a Chicago site. Spoor also outlined the company’s clinical strategy, which includes three programs in development for melanoma, neuroendocrine tumors, and FAP-targeting, with expectations to report safety and efficacy data from each this year. He recounted that the company’s founders initially aimed to design a safer drug for pediatric neuroendocrine tumors, which ultimately proved safer for adults as well. Spoor emphasized that investment in infrastructure, such as manufacturing capacity, is a key priority alongside advancing the pipeline and regulatory progress.

Recent appearances

  • Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor

    April 05, 2026 · 📺 Life Science Connect

    On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging again and why biodistribution is the make-or-break variable when your payload is a radioactive isotope. Thijs discusses the reasons behind Perspective's investment in a proprietary generator for therapeutic production, manufacturing and delivery strategy, workforce constraints, and building a clinical strategy around receptor positivity across tumor types. Access this and hundreds of episodes o…

    Watch on YouTube ↗

  • Episode 120 Thijs Spoor - CEO Perspective Therapeutics

    February 24, 2026 · 📺 The Biohub

    So welcome back to another episode of the Biohub today I'm joined by Tespore CEO of Perspective Therapeutics one of the most ...

    Watch on YouTube ↗

  • Thijs Spoor - CEO, Perspective Therapeutics - Targeted Alpha Particle Therapy To Transform Cancer

    November 21, 2025 · 📺 Progress, Potential, and Possibilities

    Thijs Spoor is Chief Executive Officer at Perspective Therapeutics ( https://perspectivetherapeutics.com/ ), a clinical-stage, radiopharmaceutical company that is pioneering innovative treatments for cancers. The Company’s proprietary technology utilizes the alpha emitting isotope Pb-212 to deliver powerful radiation directly to cancer cells via high-affinity targeting peptides. Prior to this, Thijs was the Chairman at Verifi H2O. Thijs also held the position of Chief Executive Officer at Viewpoint Molecular Targeting, Inc. and KBP BioSciences. Thijs also has served as CEO at AzurRx BioPharm…

    Watch on YouTube ↗

  • Viewpoint Molecular Targeting: Targeted Cancer Therapies

    February 09, 2023 · 📺 LilaMax Media

    Jane King interviews Thijs Spoor, CEO, Viewpoint Molecular Targeting. https://viewpointmt.com/ Innovators with Jane King profiles tech companies and thought leaders in the space. We're showing you a glimpse of the future. Viewpoint Molecular Targeting® is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. Viewpoint’s leading Pb-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary imagin…

    Watch on YouTube ↗

  • AzurRx Cultivates Therapeutic Proteins for GI Disorder Treatment

    November 02, 2017 · 📺 Modern Wall Street

    11/02/17 AzurRx BioPharma CEO and President, Thijs Spoor, provides a closer look at the two products in the development pipeline: MS1819, a recombinant lipase for the EPI treatment and AZX1101, a recombinant enzyme for the preventing infection of C.difficile. Subscribe NOW to Modern Wall Street: http://bit.ly/2wsU9rO Get more Modern Wall Street: Like Modern Wall Street:   / modernwallstreet   Follow Modern Wall Street:   / modernwallst   Insta Follow:   / modernwallstreet  

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →